Results 21 to 30 of about 2,564 (175)

Ciprofol May Represent a Useful Sedative Option for Gastrointestinal Endoscopy. [PDF]

Dig Endosc
Digestive Endoscopy, Volume 38, Issue 5, May 2026.
Yamamura T, Nakamura M, Kawashima H.
europepmc   +2 more sources

Effects of remimazolam versus dexmedetomidine on recovery after transcatheter aortic valve replacement under monitored anesthesia care: a propensity score-matched, non-inferiority study [PDF]

Korean Journal of Anesthesiology
Background Minimalist transcatheter aortic valve replacement (TAVR) under monitored anesthesia care (MAC) emphasizes early recovery. Remimazolam is a novel benzodiazepine with a short recovery time.
Ji-Hyeon Kim, Jae-Sik Nam, Wan-Woo Seo, Kyung-Woon Joung, Ji-Hyun Chin, Wook-Jong Kim, Dae-Kee Choi, In-Cheol Choi   +7 more
doaj   +1 more source

Remimazolam anesthesia for cardiac surgery with cardiopulmonary bypass: a case report

JA Clinical Reports, 2021
Background Remimazolam has less cardiovascular depressant effects than propofol in non-cardiac surgical patients. However, the efficacy and safety of remimazolam in cardiac surgery with cardiopulmonary bypass (CPB) have not been reported.
Kota Saito, Sho Ohno, Makishi Maeda, Naoyuki Hirata, Michiaki Yamakage   +4 more
doaj   +1 more source

The hemodynamic stability of remimazolam compared with propofol in patients undergoing endoscopic submucosal dissection: A randomized trial

Frontiers in Medicine, 2022
ObjectiveHypotension is common in propofol anesthesia. Whether remimazolam could reduce intraoperative hypotension remains unknown. We therefore tested the primary hypothesis that remimazolam reduces the incidence of intraoperative hypotension compared ...
Yuwei Qiu, Yuwei Qiu, Wei Gu, Mingye Zhao, Yunyun Zhang, Jingxiang Wu, Jingxiang Wu   +6 more
doaj   +1 more source

Anesthetic management with remimazolam in a patient with Child-Pugh C liver cirrhosis: a case report

JA Clinical Reports, 2022
Background Remimazolam is a new ultra-short-acting benzodiazepine, and its sedative effect is prolonged in patients with hepatic impairment. This is the first report of remimazolam anesthesia in a patient with Child-Pugh C liver cirrhosis.
Satoshi Uchida, Daiki Takekawa, Eiji Hashiba, Reiko Kudo, Kazuyoshi Hirota   +4 more
doaj   +1 more source

Comparison of postoperative nausea and vomiting between remimazolam and propofol: a propensity score-matched, retrospective, observational, single-center cohort study [PDF]

Korean Journal of Anesthesiology, 2023
Background Remimazolam is a novel ultrashort-acting benzodiazepine that has recently become available for general anesthesia. However, the incidence of postoperative nausea and vomiting (PONV) associated with remimazolam remains unknown.
Yuji Suzuki, Shingo Kawashima, Hiroshi Makino, Matsuyuki Doi, Yoshiki Nakajima   +4 more
doaj   +1 more source

Intraoperative responses of motor evoked potentials to the novel intravenous anesthetic remimazolam during spine surgery: a report of two cases

JA Clinical Reports, 2020
Background Remimazolam is a novel short-acting benzodiazepine characterized by metabolism independent from organ function. We report intraoperative MEP responses of two patients who underwent spine surgery under general anesthesia using remimazolam. Case
Takashi Kondo, Yukari Toyota, Soshi Narasaki, Tomoyuki Watanabe, Hirotsugu Miyoshi, Noboru Saeki, Yasuo M. Tsutsumi   +6 more
doaj   +1 more source

Remimazolam Anaphylaxis during Induction of General Anesthesia Confirmed by Provocation Test—A Case Report and Literature Review

Medicina, 2023
Background: Remimazolam besylate, a newly developed drug, is linked to various anaphylaxis cases. We present a case of remimazolam anaphylaxis confirmed using a provocation test.
Sangho Lee, Joyoung Park, Na Hei Kim, Halin Hong, Kyoung Hee Sohn, Hee Yong Kang, Mi Kyeong Kim, Ann Hee You   +7 more
doaj   +1 more source

Remimazolam-Based Anesthesia in Patients with Heart Failure Due to Mitral Regurgitation and Low Left Ventricular Function: A Case Series

Medicina, 2023
Background and Objectives: Remimazolam is a new ultrashort-acting benzodiazepine anesthetic. Remimazolam appears to be useful in patients with severe valvular disease because of its minimal cardiovascular impact.
Atsuhiro Kitaura, Hiroatsu Sakamoto, Shinichi Hamasaki, Shota Tsukimoto, Yasufumi Nakajima   +4 more
doaj   +1 more source

A population pharmacodynamic Markov mixed‐effects model for determining remimazolam‐induced sedation when co‐administered with fentanyl in procedural sedation

Clinical and Translational Science, 2021
The clinical effects of remimazolam (an investigational, ultra‐short acting benzodiazepine being studied in procedural sedation) were measured using the Modified Observer’s Assessment of Awareness/Sedation Scale (MOAA/S).
Jie Zhou, Laura Curd, Lauren R. L. Lohmer, Natalie Delpratt, Joachim Ossig, Frank Schippers, Thomas Stoehr, Virginia D. Schmith   +7 more
doaj   +1 more source